Optimizing rituximab therapy for neuromyelitis optica

被引：0
|
作者：
Dean M. Wingerchuk
Brian G. Weinshenker
机构：
[1] Mayo Clinic,Department of Neurology, Division of Multiple Sclerosis and Autoimmune Neurology
[2] Mayo Clinic,undefined
来源：
Nature Reviews Neurology | 2011年 / 7卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Rituximab is an immunosuppressive monoclonal antibody therapy that is used in some cases to help prevent relapses of neuromyelitis optica, an inflammatory CNS demyelinating disease. A new study provides evidence supporting efficacy and a strategy for optimizing the timing of repeated courses of treatment for the individual patient.
引用
收藏
页码：664 / 665
页数：1
相关论文
共 50 条
  • [1] WHITE MATTER DISEASE Optimizing rituximab therapy for neuromyelitis optica
    Wingerchuk, Dean M.
    Weinshenker, Brian G.
    [J]. NATURE REVIEWS NEUROLOGY, 2011, 7 (12) : 664 - 665
  • [2] Outcome of rituximab therapy in refractory neuromyelitis optica
    Kurian, Sonu
    Marimuthu, Jawahar
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [3] Rituximab Therapy for Double Seronegative Neuromyelitis Optica Spectrum Disease
    Saballegue, Jose Carlos D.
    Tiongson, Ma Luisa Gwenn P.
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (05)
  • [4] Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO)
    Dembinsky, A. Vaknin
    Charbit, H.
    Brill, L.
    Abramsky, O.
    Wahnon, D.
    Ben-Dov, I.
    Lavon, I.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 168 - 168
  • [5] Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO)
    Adi Vaknin-Dembinsky
    Hanna Charbit
    Livnat Brill
    Oded Abramsky
    Devorah Gur-Wahnon
    Iddo Z. Ben-Dov
    Iris Lavon
    [J]. Journal of Neuroinflammation, 13
  • [6] Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO)
    Vaknin-Dembinsky, Adi
    Charbit, Hanna
    Brill, Livnat
    Abramsky, Oded
    Gur-Wahnon, Devorah
    Ben-Dov, Iddo Z.
    Lavon, Iris
    [J]. JOURNAL OF NEUROINFLAMMATION, 2016, 13
  • [7] Efficacy of rituximab in refractory neuromyelitis optica
    Collongues, N.
    Brassat, D.
    Maillart, E.
    Labauge, P.
    Ouallet, J. C.
    Carra-Dalliere, C.
    Moreau, T.
    Bourre, B.
    Papeix, C.
    Brochet, B.
    Audoin, B.
    Vukusic, S.
    de Seze, J.
    Marignier, R.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (07) : 955 - 959
  • [8] Efficacy of rituximab in refractory neuromyelitis optica
    Collongues, N.
    Brassat, D.
    Maillart, E.
    Labauge, P.
    Ouallet, J. -C.
    Carra-Dalliere, C.
    Moreau, T.
    Bourre, B.
    Papeix, C.
    Audoin, B.
    Brochet, B.
    Vukusic, S.
    De Seze, J.
    Marignier, R.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 78 - 79
  • [9] Efficacy of rituximab in refractory neuromyelitis optica
    Collongues, N.
    Brassat, D.
    Maillart, E.
    Labauge, P.
    Ouallet, J. -C.
    Dalliere, C. Carra
    Moreau, T.
    Bourre, B.
    Papeix, A. -C.
    Audouin, B.
    Brochet, B.
    Vukusic, S.
    De Seze, J.
    Marignier, R.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 86 - 86
  • [10] Rituximab in neuromyelitis optica: A review of literature
    Ericka Wong
    Vijay A Vishwanath
    Ilya Kister
    [J]. World Journal of Neurology, 2015, (01) : 39 - 46
12345